 ErbB Receptors
"ErbB Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of structurally-related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS.
| Descriptor ID |
D066246
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009 D12.776.543.750.630.009 D12.776.543.750.750.400.074
|
| Concept/Terms |
ErbB Receptors- ErbB Receptors
- Receptors, ErbB
- Receptors, Epidermal Growth Factor-Urogastrone
- Receptors, Epidermal Growth Factor Urogastrone
- Receptors, Epidermal Growth Factor
- EGF Receptors
- Receptors, EGF
- Epidermal Growth Factor Receptor Family Proteins
- HER Family Receptors
- Family Receptors, HER
- Receptors, HER Family
- Erb-b2 Receptor Tyrosine Kinases
- Erb b2 Receptor Tyrosine Kinases
|
Below are MeSH descriptors whose meaning is more general than "ErbB Receptors".
Below are MeSH descriptors whose meaning is more specific than "ErbB Receptors".
This graph shows the total number of publications written about "ErbB Receptors" by people in this website by year, and whether "ErbB Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 1 | 2 | 3 | | 1991 | 1 | 2 | 3 | | 1992 | 1 | 0 | 1 | | 1993 | 1 | 1 | 2 | | 1994 | 5 | 2 | 7 | | 1995 | 2 | 3 | 5 | | 1996 | 2 | 2 | 4 | | 1997 | 2 | 2 | 4 | | 1998 | 2 | 1 | 3 | | 1999 | 5 | 0 | 5 | | 2000 | 2 | 2 | 4 | | 2001 | 2 | 2 | 4 | | 2002 | 8 | 1 | 9 | | 2003 | 6 | 6 | 12 | | 2004 | 5 | 4 | 9 | | 2005 | 13 | 4 | 17 | | 2006 | 23 | 12 | 35 | | 2007 | 13 | 3 | 16 | | 2008 | 12 | 5 | 17 | | 2009 | 9 | 8 | 17 | | 2010 | 16 | 10 | 26 | | 2011 | 7 | 4 | 11 | | 2012 | 10 | 7 | 17 | | 2013 | 10 | 7 | 17 | | 2014 | 5 | 8 | 13 | | 2015 | 6 | 10 | 16 | | 2016 | 15 | 11 | 26 | | 2017 | 12 | 10 | 22 | | 2018 | 3 | 11 | 14 | | 2019 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Peterman E, Gibieža P, Schafer J, Skeberdis VA, Kaupinis A, Valius M, Heiligenstein X, Hurbain I, Raposo G, Prekeris R. The post-abscission midbody is an intracellular signaling organelle that regulates cell proliferation. Nat Commun. 2019 07 18; 10(1):3181.
-
Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2019 05; 153(2):335-342.
-
Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, Borghaei H, West J, Kirpalani P, Morris D, Lee C, Pecot CV, Zagar T, Stinchcombe T, Pennell N. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun. 2019; 19:100126.
-
Ohm AM, Affandi T, Reyland ME. EGF receptor and PKCd kinase activate DNA damage-induced pro-survival and pro-apoptotic signaling via biphasic activation of ERK and MSK1 kinases. J Biol Chem. 2019 03 22; 294(12):4488-4497.
-
Cho SK, Su LJ, Mao C, Wolenski CD, Flaig TW, Park W. Multifunctional nanoclusters of NaYF4:Yb3+,Er3+ upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer. Mater Sci Eng C Mater Biol Appl. 2019 Apr; 97:784-792.
-
Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer. 2019 04 01; 125(7):1038-1049.
-
Astashchanka A, Shroka TM, Jacobsen BM. Mucin 2 (MUC2) modulates the aggressiveness of breast cancer. Breast Cancer Res Treat. 2019 Jan; 173(2):289-299.
-
Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann Oncol. 2018 10 01; 29(10):2143.
-
Brasino M, Roy S, Erbse AH, He L, Mao C, Park W, Cha JN, Goodwin AP. Anti-EGFR Affibodies with Site-Specific Photo-Cross-Linker Incorporation Show Both Directed Target-Specific Photoconjugation and Increased Retention in Tumors. J Am Chem Soc. 2018 09 19; 140(37):11820-11828.
-
Bauer AK, Umer M, Richardson VL, Cumpian AM, Harder AQ, Khosravi N, Azzegagh Z, Hara NM, Ehre C, Mohebnasab M, Caetano MS, Merrick DT, van Bokhoven A, Wistuba II, Kadara H, Dickey BF, Velmurugan K, Mann PR, Lu X, Barón AE, Evans CM, Moghaddam SJ. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. JCI Insight. 2018 08 09; 3(15).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|